文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

直肠间隔物在高剂量前列腺癌SABR中的多中心二期试验

A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-03-19

多中心二期试验评估直肠周围水凝胶间隔物能否降低高剂量(>40 Gy)SABR后急性前列腺周围直肠溃疡事件。无≥3级晚期胃肠道毒性,4年无生化失败生存率93.8%。

要点

  • 直肠间隔物使高剂量SABR后急性直肠溃疡发生率降至14.3%,显著低于历史对照。
  • 所有溃疡均为1-2级,8个月内消退,无≥3级晚期胃肠道毒性。
  • 4年无生化失败生存率93.8%,提示高剂量SABR联合间隔物安全有效。

核心结论

  • 高剂量SABR前放置临时水凝胶间隔物并采用严格剂量约束,可显著降低直肠溃疡事件发生率。

研究设计与样本

  • 多中心二期前瞻性试验,纳入≤T2c、GG1-3、PSA≤15 ng/mL、AUA-SI≤18、腺体体积≤80 cm3的前列腺癌患者。
  • 随访期间系列肛门镜检查评估直肠壁,主要终点为9个月内急性前列腺周围直肠溃疡事件从>90%降至<70%。

主要发现

  • 急性前列腺周围溃疡见于6/42例(14.3%,95%CI 6.0%-27%,P<.001),中位出现时间2.9个月(范围1.7-5.6个月)。
  • 所有溃疡(1级5例,2级1例)在发生后8个月内复查肛门镜均消退。
  • 无≥3级晚期胃肠道毒性,晚期2级胃肠道毒性发生率14.3%,3年时患病率0%。
  • 任何领域均无>3级毒性,4年无生化失败生存率93.8%(95%CI 85.2%-100.0%)。

关键数值与推荐

  • 入组标准:分期≤T2c、GG1-3、PSA≤15 ng/mL、AUA-SI≤18、腺体体积≤80 cm3。
  • SABR剂量:45 Gy分5次,隔日照射,仅前列腺。
  • 主要终点:9个月内急性直肠溃疡事件从>90%降至<70%,实际14.3%(95%CI 6.0%-27%,P<.001)。

临床怎么用

  • 对符合条件的局限性前列腺癌患者,高剂量SABR前可考虑放置直肠周围水凝胶间隔物以降低直肠溃疡风险。
  • 治疗中应遵循严格剂量约束,并可通过肛门镜监测急性直肠溃疡事件。

局限性

  • 单臂二期试验,非随机对照,样本量较小(42例可分析)。
  • 随访时间有限,中位48个月,长期疗效和毒性需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-dose SABR for prostate cancer offers the radiobiologic potency of the most intensified radiation therapy regimens but was associated with >90% rates of ulceration of the anterior rectal wall on endoscopic assessment; this infrequently progressed to severe rectal toxicity in prior prospective series. A multi-institutional phase 2 prospective trial was conducted to assess whether placement of a perirectal hydrogel spacer would reduce acute periprostatic rectal ulcer events after high-dose (>40 Gy) SABR. METHODS AND MATERIALS: Eligible patients included men with stage ≤T2c localized grade group 1 to 3 prostate cancer, a prostate-specific antigen (PSA) level ≤15 ng/mL, American Urological Association Symptom Index = AUA-SI scores ≤18, and a gland volume ≤80 cm3. Patients underwent perirectal hydrogel spacer placement, followed by SABR of 45 Gy in 5 fractions every other day to the prostate only. Androgen deprivation was not allowed except for cytoreduction. The rectal wall was directly assessed by serial anoscopy during follow-up to determine whether the spacer would reduce acute periprostatic rectal ulcer events from >90% to <70% within 9 months of treatment. RESULTS: Forty-four men were enrolled and 43 were eligible for protocol analysis. The median follow-up for surviving patients was 48 months. Acute periprostatic ulcers were observed in 6 of 42 patients (14.3%; 95% confidence interval, 6.0%-27%; P < .001) at a median of 2.9 months posttreatment (range, 1.7-5.6 months). All ulcers (grade 1, 5 ulcers; grade 2, 1 ulcer) resolved on repeat anoscopy within 8 months of incidence. There were no grade ≥3 late gastrointestinal toxicities; the incidence of late grade-2 gastrointestinal toxicities was 14.3%, with a prevalence at 3 years of 0%. No toxicities greater than grade 3 occurred in any domain. Four-year freedom from biochemical failure was 93.8% (95% CI, 85.2%-100.0%). CONCLUSIONS: Temporary hydrogel spacer placement before high-dose SABR treatment for localized prostate cancer and use of strict dose constraints are associated with a significant reduction in the incidence of rectal ulcer events compared with prior phase 1/2 trial results.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Folkert MR, Zelefsky MJ, Hannan R, et al. A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33753140. doi:10.1016/j.ijrobp.2021.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。